Click for new scientific resources and news about Corona[COVID-19]

Paper Information

Journal:   JOURNAL OF ISFAHAN MEDICAL SCHOOL (I.U.M.S)   3RD WEEK NOVEMBER 2017 , Volume 35 , Number 447 ; Page(s) 1242 To 1248.
 
Paper: 

COMPARISON OF CITALOPRAM AND METACOGNITIVE THERAPY ON DEPRESSION IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER

 
 
Author(s):  KHEIRABADI GHOLAMREZA, YOUSEFIAN ZAHRA*, GHASEMI NEZAMADDIN, ZAMANI MAJID, MARACY MOHAMMAD REZA
 
* BEHAVIORAL SCIENCES RESEARCH CENTER, DEPARTMENT OF PSYCHIATRY, SCHOOL OF MEDICINE, ISFAHAN UNIVERSITY OF MEDICAL SCIENCES, ISFAHAN, IRAN
 
Abstract: 

Background: Major depressive disorder (MDD) is a prevalent and devastating psychiatric disorder worldwide that needs multidimensional interventions. Metacognitive treatment is a new psychotherapeutic approach of some psychiatric disorders. This study was conducted to comparatively evaluate the impact of citalopram and metacognitive interventions on major depressive disorder.
Methods: This was a clinical trial study with a pretest/posttest design. After selection of objects, the eligible patients were randomly assigned into three groups of citalopram (n=12), metacognitive intervention (n=16), and waiting list (n=8). One experimental group received ten 1-houre sessions of metacognitive therapy; 10-40 mg citalopram was administered to other group; and third group did not receive any interventions and placed on waiting list. Outcome measures were done using Beck Depression Inventory (BDI), Metacognitions Questionnaire-30 (MCQ30), and Cognitive Emotion Regulation Questionnaire (CERQ) before and after interventions. Data analysis was performed using ANOVA and post hoc tests.
Findings: There was significant difference between the groups in terms of symptom of depression, metacognition, and emotion regulation before and after intervention. In term of metacognition, only metacognitive therapy was useful (P=0.010). Symptom of depression were improved significantly with metacognitive therapy (P=0.007); but in pharmacotherapy, despite clinical improvement, there was not any statistically significant improvement (P=0.070). In addition, emotion regulation was improved with metacognitive therapy (P=0.020).
Conclusion: Metacognitive therapy could be used in major depressive disorder. In addition, this intervention could lead to higher level of cognitive emotion regulation.

 
Keyword(s): CITALOPRAM, METACOGNITION, EMOTION, MAJOR DEPRESSIVE DISORDER
 
 
References: 
  • Not Registered.
  •  
  •  
 
Citations: 
  • Not Registered.
 
+ Click to Cite.
APA: Copy

KHEIRABADI, G., & YOUSEFIAN, Z., & GHASEMI, N., & ZAMANI, M., & MARACY, M. (2017). COMPARISON OF CITALOPRAM AND METACOGNITIVE THERAPY ON DEPRESSION IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER. JOURNAL OF ISFAHAN MEDICAL SCHOOL (I.U.M.S), 35(447 ), 1242-1248. https://www.sid.ir/en/journal/ViewPaper.aspx?id=569356



Vancouver: Copy

KHEIRABADI GHOLAMREZA, YOUSEFIAN ZAHRA, GHASEMI NEZAMADDIN, ZAMANI MAJID, MARACY MOHAMMAD REZA. COMPARISON OF CITALOPRAM AND METACOGNITIVE THERAPY ON DEPRESSION IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER. JOURNAL OF ISFAHAN MEDICAL SCHOOL (I.U.M.S). 2017 [cited 2021August01];35(447 ):1242-1248. Available from: https://www.sid.ir/en/journal/ViewPaper.aspx?id=569356



IEEE: Copy

KHEIRABADI, G., YOUSEFIAN, Z., GHASEMI, N., ZAMANI, M., MARACY, M., 2017. COMPARISON OF CITALOPRAM AND METACOGNITIVE THERAPY ON DEPRESSION IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER. JOURNAL OF ISFAHAN MEDICAL SCHOOL (I.U.M.S), [online] 35(447 ), pp.1242-1248. Available: https://www.sid.ir/en/journal/ViewPaper.aspx?id=569356.



 
 
Persian Abstract Yearly Visit 54
 
 
Latest on Blog
Enter SID Blog